These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
93 related articles for article (PubMed ID: 3132332)
1. Deconvolution analysis of the regeneration process of mitomycin C from prodrug in a muscle perfusion system based on statistical moment theory. Kakutani T; Atsumi R; Sumimoto E; Hashida M Chem Pharm Bull (Tokyo); 1987 Dec; 35(12):4907-14. PubMed ID: 3132332 [No Abstract] [Full Text] [Related]
2. A new method for assessment of drug disposition in muscle: application of statistical moment theory to local perfusion systems. Kakutani T; Yamaoka K; Hashida M; Sezaki H J Pharmacokinet Biopharm; 1985 Dec; 13(6):609-31. PubMed ID: 3938814 [TBL] [Abstract][Full Text] [Related]
3. Disposition characteristics of lipophilic mitomycin C prodrug in an intra-arterial muscle infusion system. Kakutani T; Suematsu Y; Cheah WY; Sumimoto E; Hashida M Chem Pharm Bull (Tokyo); 1987 Dec; 35(12):4898-906. PubMed ID: 3132331 [No Abstract] [Full Text] [Related]
4. Disposition characteristics of mitomycin C-dextran conjugate in normal and tumor-bearing muscles of rabbits. Atsumi R; Endo K; Kakutani T; Takakura Y; Hashida M; Sezaki H Cancer Res; 1987 Nov; 47(21):5546-51. PubMed ID: 2444332 [TBL] [Abstract][Full Text] [Related]
5. Effect of plasma protein binding on drug disposition in muscle tissue: application of statistical moment analysis and network theory to in situ local single-pass perfusion system. Kakutani T; Sumimoto E; Hashida M J Pharmacokinet Biopharm; 1988 Apr; 16(2):129-49. PubMed ID: 3418491 [TBL] [Abstract][Full Text] [Related]
6. Absorption characteristics of the lipophilic prodrug of mitomycin C from injected liposomes or an emulsion. Sasaki H; Kakutani T; Hashida M; Sezaki H J Pharm Pharmacol; 1985 Jul; 37(7):461-5. PubMed ID: 2863347 [TBL] [Abstract][Full Text] [Related]
7. A new method for assessment of drug absorption from muscle: application of a local perfusion system. Nara E; Hatono T; Hashida M; Sezaki H J Pharm Pharmacol; 1991 Apr; 43(4):272-4. PubMed ID: 1676741 [TBL] [Abstract][Full Text] [Related]
8. Absorption characteristics of macromolecular prodrugs of mitomycin C following intramuscular administration. Takakura Y; Mori K; Hashida M; Sezaki H Chem Pharm Bull (Tokyo); 1986 Apr; 34(4):1775-83. PubMed ID: 3087640 [No Abstract] [Full Text] [Related]
9. Specific activation of the prodrug mitomycin phosphate by a bispecific anti-CD30/anti-alkaline phosphatase monoclonal antibody. Sahin U; Hartmann F; Senter P; Pohl C; Engert A; Diehl V; Pfreundschuh M Cancer Res; 1990 Nov; 50(21):6944-8. PubMed ID: 2170012 [TBL] [Abstract][Full Text] [Related]
10. Reductive activation of mitomycin C. Hoey BM; Butler J; Swallow AJ Biochemistry; 1988 Apr; 27(7):2608-14. PubMed ID: 3132971 [TBL] [Abstract][Full Text] [Related]
11. Liposomal sustained-release delivery systems for intravenous injection. III. Antitumor activity of lipophilic mitomycin C prodrug-bearing liposomes. Tokunaga Y; Iwasa T; Fujisaki J; Sawai S; Kagayama A Chem Pharm Bull (Tokyo); 1988 Sep; 36(9):3565-73. PubMed ID: 3149215 [No Abstract] [Full Text] [Related]
12. Disposition and pharmacokinetics of a polymeric prodrug of mitomycin C, mitomycin C-dextran conjugate, in the rat. Hashida M; Kato A; Takakura Y; Sezaki H Drug Metab Dispos; 1984; 12(4):492-9. PubMed ID: 6148218 [TBL] [Abstract][Full Text] [Related]
13. Disposition of anticancer drugs after bolus arterial administration in a tissue-isolated tumor perfusion system. Ohkouchi K; Imoto H; Takakura Y; Hashida M; Sezaki H Cancer Res; 1990 Mar; 50(5):1640-4. PubMed ID: 2105843 [TBL] [Abstract][Full Text] [Related]
14. Liposomal sustained-release delivery systems for intravenous injection. II. Design of liposome carriers and blood disposition of lipophilic mitomycin C prodrug-bearing liposomes. Tokunaga Y; Iwasa T; Fujisaki J; Sawai S; Kagayama A Chem Pharm Bull (Tokyo); 1988 Sep; 36(9):3557-64. PubMed ID: 3149214 [No Abstract] [Full Text] [Related]
15. [Effect of the pretreatment with Escherichia coli culture filtrate (communin) on the mitomycin c concentration in vivo]. Kojima R; Nishimura M Igaku To Seibutsugaku; 1971 Nov; 83(5):259-63. PubMed ID: 4948681 [No Abstract] [Full Text] [Related]
16. Some perspectives on targeted delivery with prodrugs. Sinkula AA Ann N Y Acad Sci; 1987; 507():281-8. PubMed ID: 3327417 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic analysis of drug absorption from muscle based on a physiological diffusion model: effect of molecular size on absorption. Nara E; Masegi M; Hatono T; Hashida M Pharm Res; 1992 Feb; 9(2):161-8. PubMed ID: 1553335 [TBL] [Abstract][Full Text] [Related]
18. Specificity of antisera produced against mitomycin C. Fujiwara K; Saikusa H; Kitagawa T; Takahashi S; Konishi Y Cancer Treat Rep; 1983 Dec; 67(12):1079-84. PubMed ID: 6418380 [TBL] [Abstract][Full Text] [Related]
19. Preparation and properties of a mitomycin C-albumin conjugate. Kaneo Y; Tanaka T; Iguchi S Chem Pharm Bull (Tokyo); 1990 Sep; 38(9):2614-6. PubMed ID: 2126750 [TBL] [Abstract][Full Text] [Related]
20. [Preclinical studies of intra-arterial chemotherapy using mitomycin C microspheres]. Endoh F; Fujimoto S; Kitsukawa Y; Miyazaki M; Shimura T; Sugasawa H; Takahashi O; Kurihara M; Kawata S; Okui K Gan To Kagaku Ryoho; 1984 May; 11(5):1092-7. PubMed ID: 6426403 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]